Concern of underdiagnosing asthma–COPD overlap syndrome if age limit of 40 years for asthma is used
- 1Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland
- 2University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland
- Minna Tommola, Dept of Respiratory Medicine, Seinäjoki Central Hospital, FIN-60220 Seinäjoki, Finland. E-mail: minna.tommola{at}epshp.fi
Abstract
The suggested asthma-onset age limit of 40 as a criterion for ACOS may lead to severe underdiagnosis of ACOS http://ow.ly/rVSk30ckrOq
To the Editor:
In a recent issue of the European Respiratory Journal, Sin et al. [1] presented recommendations on the definition of asthma–chronic obstructive pulmonary disease overlap syndrome (ACOS). The presented conclusions, based on a round table discussion, are very important and notable, especially considering the current lack of specific clinical criteria for ACOS. One of the key recommendations is that asthma or atopy should be diagnosed before age of 40 years (or patients should have very large airway reversibility) in order to fulfil the criteria of ACOS. However, the scientific basis of using the 40-year cut-off remains debatable. In addition, the proposal raises a major concern of underdiagnosing adult-onset asthma and ACOS if the suggested age limit is used.
ACOS has been described to develop mainly by two pathways: 1) patients with previous COPD develop asthma-like symptoms and/or asthmatic characteristics (e.g. large reversibility of the airways); or 2) patients with previous asthma continue smoking and develop nonreversible bronchial obstruction, which indicates COPD [2, 3]. The prevalence of ACOS is suggested to be 12–55% among patients with COPD and 13–61% among patients with asthma [2]. These numbers reflect the relatively large impact of ACOS and necessitate diagnostic accuracy.
Based on cluster analyses, different phenotypes have been recognised in asthma and the age of onset has been found to be a key factor distinguishing these phenotypes [4, 5]. Early-onset asthma has typically been associated with atopy and allergies, and characterised by a good response to inhaled corticosteroids and relatively high remission rate [4, 5]. Adult-onset asthma, on the other hand, has received less attention. Recent studies have suggested adult-onset asthma to have lower remission rates [5, 6], more rapid loss of lung function [5] and poorer prognosis [6, 7]. In a recent study of age-specific incidence of new asthma diagnoses in Finland, it was reported that most diagnoses of persistent asthma are actually made in adulthood [8]. In a US-based study, the adult-onset phenotype was reported to dominate especially among women [9]. Moreover, in a clinical cohort of consecutive, new adult-onset asthma patients (Seinäjoki Adult Asthma Study [6, 10]), the mean±sd age of asthma onset was found to be 46±13.7 years, which is substantially higher than the suggested limit [6, 10]. These findings raise a question of whether the age limit of 40 years is actually applicable to real-life clinical work.
In Finland, every patient with persistent asthma is entitled to asthma reimbursement by the Social Insurance Institution of Finland (SII). The number of new asthma reimbursements reflects the number of novel asthma diagnoses made. We obtained numbers of patients from the SII and evaluated the age at which the reimbursement was obtained in Finland during 2012–2013, in order to evaluate whether diagnoses of persistent asthma were made either before or after 40 years of age. Data acquisition and calculation of novel asthma medication reimbursements were made as previously described [8].
In 2012–2013, in Finland (population 5.4 million), 26 281 new patients were entitled to special reimbursement for their asthma medication (13 941 females and 12 340 males). Of these, only 12 095 (46.0%) persons belonged to age group 0–39 years, indicating that a majority (54.0%) of new patients who obtained special asthma medication reimbursement were older than 40 years (figure 1). More than half (57.9%) of females were ≥40 years; in contrast, 50.5% of men obtained asthma reimbursement before their 40th birthday (figure 1). In conclusion, these results further suggest that most asthma is diagnosed after 40 years of age, and thus emphasise the impact and importance of adult-onset asthma. The criterion for asthma reimbursement in Finland is variable airway obstruction demonstrated by objective lung function measurements [8]; thus, misclassified COPD does not explain the result, even though this analysis contains patients with a history of smoking.
The perception of asthma being merely a childhood-onset disease persists; however, the adult-onset phenotype of asthma has been identified in several studies and is recognised by guidelines. There is already evidence that a majority of persistent asthma may actually start in adulthood [8, 9], making it necessary to take patients with adult-onset asthma into consideration when the starting age of asthma is recommended as a diagnostic criterion. In order to obtain a diagnosis, and administer good and increasingly personalised therapy to our ACOS patients, the diagnostics must be accurate and sensitive regardless of sex, age and smoking status. Using the suggested age limit of 40 years as a criterion for ACOS may lead to severe underdiagnosis of ACOS when patients with asthma onset after 40 years of age are not included. This especially concerns women. Thus, we propose that the suggested age limit of asthma onset in the criteria of ACOS should be reconsidered.
Disclosures
Supplementary Material
P. Ilmarinen ERJ-00871-2017_Ilmarinen
H. Kankaanranta ERJ-00871-2017_Kankaanranta
M. Tommola ERJ-00871-2017_Tommola
L.E. Tuomisto ERJ-00871-2017_Tuomisto
Acknowledgements
We thank senior statistical analyser Timo Partio from the Social Insurance Institution of Finland for providing the data.
Footnotes
Support statement: This work was supported by the Finnish Anti-Tuberculosis Association Foundation (Helsinki, Finland), Tampere Tuberculosis Foundation (Tampere, Finland), Research Foundation of the Pulmonary Diseases (Helsinki), Jalmari and Rauha Ahokas Foundation (Helsinki), Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere), and Medical Research Fund of Seinäjoki Central Hospital (Seinäjoki, Finland). Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
- Received April 27, 2017.
- Accepted April 27, 2017.
- Copyright ©ERS 2017